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The fungus Aspergillus fumigatus is ubiquitous in nature and the most common cause of invasive
pulmonary aspergillosis (IPA) in patients with a compromised immune system. The development
of IPA in patients under immunosuppressive treatment or in patients with primary immunodefi-
ciency demonstrates the importance of the host immune response in controlling aspergillosis. How-
ever, study of the host-microbe interaction has been hampered by the lack of tools for their
non-invasive assessment. We developed a methodology to study the response of the host’s immune
system against IPA longitudinally in vivo by using fluorine-19 magnetic resonance imaging (19F MRI).
We showed the advantage of a perfluorocarbon-based contrast agent for the in vivo labeling
of macrophages and dendritic cells, permitting quantification of pulmonary inflammation in
different murine IPA models. Our findings reveal the potential of 19F MRI for the assessment of
rapid kinetics of innate immune response against IPA and the permissive niche generated through
immunosuppression.
INTRODUCTION
Aspergillus fumigatus is an opportunistic, potentially life-threatening fungus, which thrives mainly on
organic substrates like decaying vegetation in the soil or food. Although environmental exposure of hu-
mans to the airborne A. fumigatus conidia is common, host-pathogen interactions effectively eradicate
conidia from the pulmonary region of healthy individuals (Margalit and Kavanagh, 2015; Mccormick
et al., 2010). The key determinant of infection is thought to be the innate immune response.
A. fumigatus conidia in the alveolar space of lungs trigger pathogen recognizing receptors (PRRs), driving
the first responders of the immune system (Dagenais and Keller, 2009). Key cellular mediators of immunity
include resident alveolar macrophages, monocytes and dendritic cells for the engulfment of conidia, and
neutrophils for the destruction of hyphae using neutrophil extracellular traps (Khanna et al., 2016; Roilides
et al., 1998; Sales-campos et al., 2013; Zhang et al., 2019).
Healthy individuals effectively clear A. fumigatus, whereas infection becomes life-threatening in immuno-
compromised patients. With an increasing number of immunocompromised patients from organ trans-
plantation or cancer treatment, invasive pulmonary aspergillosis (IPA) is rapidly growing as a medical prob-
lem (Berenguer et al., 1995). The acute inflammation in the lungs of patients with IPA suggests an
underlying malfunction, rather than absence, of essential host immune components as the causative factor
(Krenke and Grabczak, 2011). Themodus operandi for the clinical use of immunosuppressive drugs mainly
includes cyclophosphamide (CY) (Emadi et al., 2009) and hydrocortisone acetate (HCA) (Garth and Steele,
2017; Shaikh et al., 2012) administered intravenously to the patients. In previous studies, it was shown that
the pathophysiology of IPA and the immune response against the fungal infection differs for each com-
pounds (Dagenais and Keller, 2009; Stephens-Romero et al., 2005). Corticosteroids treatment impairs
phagocyte function, including an abnormality in cellular migration and production of the inflammatory cy-
tokines, while leaving neutrophils intact and functional (Brummer et al., 2001; Kamberi et al., 2002; Nawada
et al., 1996). The phagocytic defect permits infection growth, which in turn drives a massive recruitment of
neutrophils to the site of infection, resulting in intensive tissue damage. By contrast, CY induces neutrope-
nia and depletes other circulating white blood cells, while leaving the local innate immune response rela-
tively intact. Here the neutropenia is thought to be critical in permitting hyphal growth and further invasion184 iScience 20, 184–194, October 25, 2019 ª 2019 The Authors.
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in the tissue (Jones et al., 2019; Kalleda et al., 2016). A key limitation of these conclusions, however, is the
reliance on invasive methods that are restricted to single time point measurements, such as immunohisto-
chemistry (Balloy et al., 2005; Wang et al., 2017). Knowledge of immune kinetics and longitudinal disease
progression is currently lacking but is essential for understanding the dynamics of these processes (Kalleda
et al., 2016). In vivo imaging techniques are potentially able to assess the host response against the infec-
tion longitudinally in individual animals.
Different imaging techniques have been used in preclinical models to characterize IPA, such as computed
tomography, positron emission tomography, bioluminescence imaging, single photon emission tomogra-
phy, proton magnetic resonance imaging (1H MRI), and fibered confocal fluorescence microscopy (Brock
et al., 2008; Poelmans et al., 2016, 2018; Rolle et al., 2016; Vanherp et al., 2018; Wang et al., 2013). Although
these approaches fulfill the non-invasive and longitudinal criteria required, they lack specific information on
inflammatory processes occurring in the host. In other disease models, ex vivo and in vivo cell labeling ap-
proaches use 1H MRI contrast agents to visualize immune cells for studying various inflammatory processes
(De Temmerman et al., 2014; Ho and Hitchens, 2004; Schwarz et al., 2012; Wu et al., 2006). However, 1HMRI
contrast agents such as (super)paramagnetic nanoparticles generate unspecific signal voids, making it diffi-
cult to locate and quantify labeled cells in vivo. Fluorine contrast agents in combination with 19F MRI may
provide an alternative, with specific and quantifiable contrast (Ebner et al., 2010; Srinivas et al., 2010a;
Zhong et al., 2015).
19F MRI is an emerging non-invasive tool, which can be applied both for imaging of ex vivo contrast
agent labeled cells after their transplantation and for in vivo labeling of cells after systemic administra-
tion of fluorinated contrast agents (Jacoby et al., 2014b; Srinivas et al., 2012, 2010b). Using fluorinated
contrast agents such as perfluoro-15-crown-5-ether nanoparticles (PFCE-NPs) in combination with 19F
MRI, one can generate highly specific MR contrast, owing to the lack of background signal. Overlaying
the 19F MR image with a conventional 1H MR image provides the necessary anatomical background
(Liang et al., 2018).
Here, we developed an imaging platform allowing non-invasive and longitudinal quantification of the de-
gree of pulmonary inflammation in IPA murine models. We showed that the in vivo labeling of immune cells
with newly developed zonyl perfluoro-15-crown-5-ether nanoparticles (ZPFCE-NPs) reveal underlying path-
ophysiological events during acute IPA using 19F MRI.RESULTS
Small-Sized Biocompatible ZPFCE-NPs Showed Efficient In Vitro Labeling of Murine
Phagocytes
To monitor the immune responses in vivo, we sought to exploit the functional property of phagocytosis for
immune cells labeling. ZPFCE-NPs label professional phagocytic cells owing to their small size (Waiczies
et al., 2011). To validate the feasibility of this strategy, Macrophages, identified by their characteristic
high surface expression of CD11b and F4/80, successfully phagocytosed ZPFCE-NPs in a dose-dependent
manner (Figure 1). ZPFCE-NP labeling of macrophages showed similar labeling efficiencies for particle con-
centrations of 1 and 10 mM (Figure 1A). We used ZPFCE-NPs incorporated with Cholesteryl BODIPY FLC 12
green fluorescent dye. These nanoparticles did not show nanotoxicity in primary macrophages upon label-
ing with relatively high concentrations, affirming their suitability for in vivo applications (Figure S1).
A key requirement for an in vivo labeling protocol is that the label does not interfere with the biological
processes being measured. To investigate whether ZPFCE-NP labeling modulates macrophage function,
we tested key innate and adaptive functions in vitro. Using cytokine secretion as a readout for innate func-
tional activation of macrophages, we found no impact of ZPFCE-NPs on spontaneous or lipopolysaccha-
ride (LPS)-induced immune activation at a dose of 1 mM and only a weak enhancement of LPS-induced
TNF-alpha production at 10 mM (Figure 2A). For the adaptive immune system, we tested the biological
effect of ZPFCE-NPs labeling on antigen-presentation by macrophages. C57BL/6 peritoneal macrophages
were pre-labeled with ZPFCE-NPs and pulsed with OVA peptide (OVA323-339) before co-culture with
OVA-reactive OT-II TCR transgenic CD4+ T cells. OT-II T cells showed efficient activation when primed
with OVA-loaded macrophages, which was unaltered by the pre-loading with ZPFCE-NPs (Figure 2B).
Together, these results demonstrate that 1 mM ZPFCE-NPs allow macrophage labeling without inducing
biological alterations to either the innate or adaptive functions of macrophages.iScience 20, 184–194, October 25, 2019 185
Figure 1. ZPFCE-NPs Allow Labeling of Macrophages
(A) Labeling of macrophages (positive cells for F4/80 and CD11b surface marker) with ZPFCE-NPs was measured in terms
of percentage uptake at variable doses of particles. Median fluorescence intensities were measured from the gated
ZPFCE-NP-labeled macrophages for each dose (mean G SD).
(B) Confocal image showing macrophages stained by F4/80 surface (red) with the ZPFCE-NPs (green), magnified
representative images show intracellular uptake of ZPFCE-NPs. Scale bar is 20mm.19F MRI Allows In Vivo Visualization and Quantification of Immune Cell Recruitment in
A. fumigatus-Infected Lungs
Having validated ZPFCE-NPs as an efficient and biologically neutral contrast agent for macrophages, we
sought to assess the in vivo utility using IPA mouse models to apply our methodology as a proof of prin-
ciple. To test the robustness of our immunomonitoring method, we used three models of pulmonary
aspergillosis with immunocompetent and immunosuppressed mice, together with non-infected mice
as control. CY or HCA immunosuppressive drugs were used to induce neutropenia and phagocytic
dysfunction in mice, respectively. Immunocompetent mice infected with A. fumigatus demonstrated a
large and rapid influx of macrophages into the lung within 4 h of infection (Figure 3A, second row
and 3B). Inflammation was quickly resolved, with a return to near-baseline macrophage levels by 24 h
(Figure 3B). By contrast, both forms of immunosuppression sharply reduced the immediate innate
response to infection, with poor influx at 4 h (Figure 3A, third and fourth row and 3B). In both cases,
this defect in the immediate response corrected with a more chronic inflammatory signal, with large
macrophage influx out to at least 3 days post infection (Figure 3B), consistent with a model where the
defective immediate response allowed infection to become invasive and chronic. We observed and
quantified a higher fluorine MRI signal intensity in the HCA mice as compared with the CY mice groups
at the site of inflammation post pulmonary infection. No detectable fluorine signal was observed from
the non-infected immunocompetent mice (N-IC).
Key differences were also observed between the immunosuppressed groups, with HCA-treated mice but
not CY-treated mice, resulting in a transient flux of macrophages into the cervical lymph nodes on day 1
post infection (Figure 3C). This indicates that HCA allows macrophage mobilization but diverts recruitment
into the draining lymph node rather than into the tissue.
To monitor progression of infection, we applied a cumulative scoring of 1H MR images based on the lung
signal intensity in all murine groups. This shows the pathophysiological changes occurring over time
following infection from day of infection (day 0) until day 3 (Figure S2A). We have observed high signal in-
tensities in the CY group where infection was more profound compared with the HCA group (Figure S2B).186 iScience 20, 184–194, October 25, 2019
Figure 2. ZPFCE-NPs Allow Labeling of Murine Macrophages without Modulating Their Innate and Adaptive
Immune Function
(A) Cytokine measurements performed on supernatants from ZPFCE-labeled macrophages in the presence and absence
of LPS. Data represent mean G SEM (n = 5, ****p < 0.0001).
(B) C57BL/6 peritoneal macrophages were pre-loaded with ZPFCE-NPs and pulsed with OVA peptide (OVA323-339) at
different concentrations, before co-culture with OT-II TCR transgenic CD4+ T cells. After 3 days of co-culture, the cells
were stained for lineage T cell markers in combination with T cell activation markers and analyzed by flow cytometry. The
percentage of CD44highCD62Llow activated T cells across variable doses of the OT-II peptide, for ZPFCE-NP-labeled and
unlabeled macrophages (mean G SEM).Together, these results both validate 19F MRI as an in vivomonitoring tool for anti-microbe responses and
indicate a critical window of response for the innate immune system against A. fumigatus invasive infection.
Distinctive Fungal Burden Depicted by Bioluminescent Imaging and Colony-Forming Units
Confirms Infection
To affirm infection and viablepulmonary fungal loadwith inflammatory processes thatwe havemonitoredby 19F
MRI, we have examined the Fluc+ A. fumigatus infection 3 days after infection by using ex vivo bioluminescent
imaging (BLI). After D-luciferin administration in the lungs, CY-treated mice showed higher BLI signal intensity
compared with the hydrocortisone-treated mice (Figure 4A). No detectable bioluminescence signal was
observed from the lungs in the two control groups, infected immunocompetent and non-infected mice. Quan-
tification of BLI signal also showed significantly high fungal infection in the CY-treated group comparedwith the
hydrocortisone-treatedgroupand infected-immunocompetentgroup (Figure 4B). This indicates strong invasion
of fungi in the lungs of the CY group owing to lack of an efficient immune response compared with the HCA
group, where the immune response prevents the growth of A. fumigatus.
For the quantification of pulmonary fungal load, we performed colony-forming unit (CFU) counting on the
cultured lung homogenates from all mice groups. We observed a significant increase in the A. fumigatus
burden in the lungs of the CY group when compared with the HCA on day 3 (Figure 4C). In contrast, N-IC
and I-IC groups did not show any fungal growth. These results together with 19F MRI suggest the early im-
mune activation in infected mice as a critical aspect for the control of potentially invasive A. fumigatus
progression.
Validation of ZPFCE-NP-Labeled Immune Cell Recruitment in the Lungs and Lymph Nodes by
Histology and Immunofluorescence Imaging
To validate our imaging results, we performed periodic acid-Schiff (PAS) staining and immunofluorescence
after sacrificing the animals 3 days after infection. Similar to 19F MRI, we observed high pulmonaryiScience 20, 184–194, October 25, 2019 187
Figure 3. 19F MRI Identifies the Differential Local Immune Response to Infection by A. fumigatus in
Immunocompromised Murine Hosts
(A) 19F MR images (fluorine signal was superimposed on anatomical 1H MR images) were obtained from HCA, CY, and
infected-immunocompetent (I-IC) mice as well as non-infected control mice (N-IC) on day 0 (4 h post infection). All mice
received systemic injection of ZPFCE-NPs on day 0 (4 h post infection) and day 1. All infected mice were imaged daily (1H
and 19F MRI). The non-infected immunocompetent (N-IC) group was followed up on day 0 and day 3. Labels for different
organs (image top left) include H, heart; L, lungs; and R, reference containing 30 mM ZPFCE-NP. Scale bar is 2.6 cm.
(B) Quantification of the 19FMR signal from the lung region was performed for all groups by comparing the signal intensity
of the lung region with a reference (R in (A) top left image) containing 30 mM ZPFCE-NPs. Data shown as meanG SEM
(*p < 0.05).
(C) 19F MRI signal was observed from the lymph node region only for mice from the HCA group on day 1. Mean 19F MR
signal intensity was quantified with respect to the 30 mM reference placed next to each animal. 19F MRI signal in
lymph nodes is indicated as hot spots overlaid over the anatomical 1H MR image (right panel). Data shown as mean G
SEM (*p < 0.05).inflammation in the lung tissue of the HCA group upon A. fumigatus challenge with minimal fungal inva-
sion. In contrast, the CY group, showed as expected fungal growth and hyphal growth formation with in-
vasion in nearby tissues and no visible inflammation (Figure 5A). The two control N-IC and I-IC mice groups
showed normal lung tissue morphology with no fungal infection on day 3, validating the 19F MRI findings.
Immunofluorescence images also showed the presence of stringent inflammation resulting in higher
influx of ZPFCE-NP-labeled macrophages and dendritic cells in the lungs of the HCA group in contrast188 iScience 20, 184–194, October 25, 2019
Figure 4. Visualization and Quantification of Fungal Load Reveals the Impaired Immune Response against
A. fumigatus Invasion in Immunocompromised Mice
(A) Ex vivo bioluminescent imaging (BLI) was performed to visualize firefly luciferase (Fluc)-expressing A. fumigatus in the
lungs 3 days after the infection. After the endpoint 19F MRI experiment, animals were sacrificed and D-luciferin was
administered into the excised lungs of murine groups of mice. Lungs were imaged immediately after D-luciferin
administration. The scale bar represents BLI signal intensity in photons flux/second. The color-coded BLI images are
overlaid onto the photographic images of lungs. Intensity thresholds for all BLI images were kept the same.
(B) BLI signal intensity from all murine groups was measured as total flux after assigning identical regions of interest on the
BLI images of lungs.
(C) Lungs were isolated 3 days after infection from all mice groups. Colony-forming units (CFUs) were manually counted
from lung homogenates 24 h after incubation at 37C. No fungi were observed in the two control groups (N-IC and I-IC).
Data are represented as mean G SEM (*p < 0.05, ****p < 0.0001). HCA n = 5, CY n = 6, I-IC n = 4, N-IC n = 3.to the CY group (Figure 5B, third and fourth row). Additionally, elevated recruitment of granulocytes was
observed near the airways of the HCA group compared with other groups. The N-IC and I-IC groups
showed no visible inflammation or infection similar to 19F MRI (Figure 5B, first and second row). We
also noticed differences in white blood cell counts, analyzed individually from the peripheral blood of
different groups on day 3, indicating severe inflammation in the HCA group reflected by an increase
in the number of neutrophils and lymphocytes in the blood in contrast to the CY group (Figure S3).
The non-infected model showed similar levels of neutrophils and lymphocytes as the I-IC model where
immune cells were in the normal range. Notably, the cervical lymph nodes of the HCA group showed
high ZPFCE-NPs accumulation (Figure S4). ZPFCE-NPs were also visualized in the OCT (optimum cutting
temperature)-embedded lungs on day 3 by ex vivo fluorescence imaging illustrating high fluorescent
signal observed both in the lungs and cervical lymph nodes, only in the HCA group (Figure S5). Briefly,
these results strongly support the 19F MRI findings, demonstrating the feasibility of our established meth-
odology for non-invasive monitoring of infection.DISCUSSION
With the increased number of immunocompromised patients, it becomes more important to closely
monitor those patients, diagnose, and follow up IPA. Among the profound number of clinical IPA cases,
90% are caused by A. fumigatus (Lin et al., 2001; Massam et al., 2011). For a better understanding of asper-
gillosis and for testing of novel antifungal compounds, preclinical animal models are essential. Although
methods for monitoring the dynamics of the immune cells upon A. fumigatus infection have been devel-
oped recently (Kalleda et al., 2016), these studies were not able to assess the interaction with the host’s im-
mune system longitudinally in vivo. Here, we have developed an approach that allows the non-invasive, dy-
namic monitoring of both inflammatory processes and the infection in three different animal models of IPA.iScience 20, 184–194, October 25, 2019 189
Figure 5. Histological Imaging Elucidates Diverse Infection and Inflammation Patterns in Immunocompromised
Groups
(A) Representative light microscopy of PAS-stained images showing histopathology from the PFA fixed lung sections of
different mice groups on day 3 post infection. Excessive immune cell infiltration near the bronchi and bronchiole upon
pulmonary A. fumigatus infection in HCA mice showing profound inflammation-induced tissue destruction. Mild fungal
infection observed in HCA mice (black arrows, HCA magnified image). Fungal dissemination shown in the CY mice
resulted in compression of lung tissue with massive hyphal growth (magnified CY image). Scale bar is 200 mm for the first
and second rows and 50 mm for magnified images (third row).
(B) Immunofluorescence microscopy performed on fresh-frozen lung tissues showing the ZPFCE-NP-labeled
macrophages (anti CD11b) and dendritic cells (anti CD11c) recruited to the bronchioles (white arrows) in the lungs of HCA
and CY mice. Granulocytes (anti-GR1) were also found to be accumulated (white arrows) in high numbers in the HCA
group compared with other groups. Scale bar is 100 mm, and staining represented as Blue = DAPI, Red = ZPFCE-NPs.
190 iScience 20, 184–194, October 25, 2019
Several cell-labeling approaches have been established to non-invasively visualize the mechanisms of im-
mune reactions involved in various diseases by tracking the loci of inflammatory immune cells using 19F MRI
(Ebner et al., 2010; Flogel et al., 2008; Jacoby et al., 2014a; Stoll et al., 2012). In this study, we focused on the
quantification and localization of inflammation in IPA murine models of immune impairments induced by
clinically used immunosuppressive drugs (Balloy et al., 2005; Stergiopoulou et al., 2007; Woodruff and He-
bert, 2002). PFCs have been used and tested as blood substitutes and thus proven to be safe in humans
(Janjic and Ahrens, 2009; Ruiz-Cabello et al., 2011). Here, we synthesized ZPFCE-NPs and studied their po-
tential for the labeling of phagocytic immune cells. It has been shown that labeling with PFCE particles of
different sizes could potentially modulate the immune function of dendritic cells (Waiczies et al., 2011). In
this study, we showed the biological compatibility of ZPFCE-NPs for in vivo studies, where labeled macro-
phages retained their antigen processing and T cell activation capacity. Compared with most other PFCs,
ZPFCE-NPs have a reduced size of280 nm (Dewitte et al., 2013).In our in vivo study, we have used 19F MRI
to quantify inflammation non-invasively and longitudinally after systemic injections of ZPFCE-NPs. The 19F
MRI signal detected in inflamed areas corresponds to the infiltration of labeled phagocytic cells in the re-
gion of interest (Flogel et al., 2008; van Heeswijk et al., 2015). We observed high 19F MRI signal intensities in
the lungs of the infected immunocompetent (I-IC) mice already 4 h after the fungal infection, which was
completely cleared after 24 h, confirming the expected eradication of A. fumigatus conidia by the immune
system. In the hydrocortisone (HCA)-treated mice, the exacerbated intrusive recruitment of immune cells
resulted in the labeling of not only tissue-resident macrophages but also dendritic cells (Temme et al.,
2012). Inflammation was found to be less pronounced in the CY-treated mice, with increased fungal inva-
sion in the lungs. We did not observe any detectable fluorine signal in the lungs from the non-infected
immunocompetent (N-IC) mice that have received ZPFCE-NPs, indicating absence of any inflammation
in the lungs. Only in HCA mice, elevated accumulation of ZPFCE-NPs was observed in the nearby cervical
lymph nodes to 3 days after infection as shown in the 19F MR images.
In addition to 19F MRI, in vivo 1HMRI in these mouse models was able to document the lesion development
occurring in the lungs upon fungal conidia challenge. As shown by our quantitative image analysis, we
observed high lung lesion formation in CY mice two and three days after infection, which is consistent
with profound fungal hyphal growth and invasion in lungs as reported before (Poelmans et al., 2016). 1H
MRI indicated only weak lesion formation in the infected HCA-treated and I-IC groups. These results
endorse the fact that the administration of CY as a frequently used immunosuppressive drug can lead to
lethal IPA with mild initial inflammation in the lungs as indicated by 19F MRI. On the contrary, hydrocorti-
sone-based immunosuppression leads to less lesion formation by A. fumigatus but triggers acute inflam-
mation leading to potentially lethal tissue destruction (Kalleda et al., 2016). The functional immune system
of the infected-immunocompetent mice resulted in the rapid initial immune reaction and complete clear-
ance of the fungi as shown in the 1H MR images and also confirmed by histology. By using 19F MRI, we were
able to monitor the intricate dynamic profile of the host-pathogen interaction in pulmonary A. fumigatus
infection in vivo. We documented the differences between immunocompetent hosts and animals treated
with two different immunosuppressive compounds. With clinically safe contrast agents like perfluoro-
carbon (PFC)-based fluorinated nanoparticles, 19F MRI not only proved to be a powerful imaging modality
for numerous preclinical studies but also showed potential for translation to humans. For immune cell im-
aging, 19FMRI has developed into a robust method for the follow-up of phagocytic cells with less success in
the tracking of non-phagocytic cells owing to the sensitivity issues of 19F MRI (Saini et al., 2019).
In summary, we demonstrated the potential of 19F MRI and perfluorocarbon-based ZPFCE-NPs by success-
ful tracking and quantifying the fluorine signal generated by innate immune cells, macrophages, and den-
dritic cells in the lungs corresponding to the intensity of local inflammation. By being able to monitor both
the infection and immune reaction in live animals over time, it is possible to make treatment decisions
rapidly and almost in real time. In the future, this will help in testing transgenic fungal strains, novel anti-
fungal drugs, or new approaches to influence the immune system. Overall, it will provide an emerging
19F MRI platform for studying not only basic mechanisms of fungal infections but also advanced immune
cell therapies in patients (Ahrens et al., 2014; Amiri et al., 2015; Fink et al., 2018; Hertlein et al., 2013).Limitations of the Study
Although the PFC-based fluorinated nanoparticles provided specific contrast for immune cell imaging in
the preclinical aspergillosis models, 19F MRI is still limited to applications where large cell numbers accu-
mulate locally. For less severe models of inflammation, the sensitivity of 19F MRI needs to be improved byiScience 20, 184–194, October 25, 2019 191
using either contrast agents with higher fluorine load or improved hardware (Khalil et al., 2019) and/or im-
age processing approaches (Liang et al., 2017). In addition, in vivo cell labeling was restricted to phagocytic
cells like macrophages. Animal models used in this study were already described by invasive methods. In
the future, a comparative experiment using a PRR knockout mouse strain instilled with a transgenic fungus
lacking a key PAMP (e.g., melanin or galactosaminoglycan) can be used as a suitable model to study the
immune response in differently modulated transgenic animals.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
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Figure S1. ZPFCE-NP labeling did not show any biological alteration of macrophages, Related to Figures 
1 and 2. High-content InCell imaging was performed to evaluate potential cellular toxicity for macrophages 
upon ZPFCE-NP labeling. Histograms revealed the relative level of cell viability, cell area, formation of 
mitochondrial reactive oxygen species (ROS) and percentage of macrophages in the total population of immune 
cells exposed to 0, 0.5, 1, 5, and 10mM of ZPFCE-NPs. Data are represented as mean± SEM of the untreated 
control values. No statistically significant differences were detected. 
  
 Figure S2. In vivo quantification of anatomical changes using 1H MR imaging confirms infection (IPA) 
and shows lesion development in immunocompromised mice, Related to Figure 3. (A) 1H MR images were 
acquired before 19F MRI acquisition using a dual-tuned MR coil. 1H MRI images were acquired daily from the 
day of infection for three days. Lesions caused by A. fumigatus infection are seen as hyperintense (bright) regions 
(arrow). (B) Quantitative estimation of lung lesion development was performed based on the image signal 
intensities by applying cumulative image scoring method. (N-IC: Non-infected immunocompetent group, n=3; 
I-IC: Infected-immunocompetent group, n=4; HCA: Hydrocortisone acetate treated group, n=5; CY: 
Cyclophosphamide treated group, n=6). Data represented as mean±SEM. (* p<0.05, ****P<0.0001). 
  
 Figure S3. Differential blood immune cell counting depicts patrolling immune cells in all murine groups, 
Related to Figures 3 and 5. Samples from peripheral blood pool was analyzed for individual mice after cardiac 
puncturing. Blood samples were collected from different groups on the experimental end-point at day 3. Numbers 
of white blood cells (WBCs), neutrophils, lymphocytes and monocytes were measured and represented for 
individual animal. 
  
 Figure S4. Visualization of ZPFCE-NPs in cervical lymph nodes confirms in vivo 19F MRI assessment for 
all mice groups, Related to Figure 3C. Fluorescent microscopy was performed on cryo-sectioned cervical lymph 
nodes where high accumulation of ZPFCE-NPs in the lymph nodes was shown in HCA group compared to other 
groups after animals have been sacrificed on day 3, after infection. Scale bar 100µm. Stainings: Blue=DAPI, 
Red=ZPFCE-NPs. 
  
 Figure S5. Ex vivo fluorescence imaging of lungs and cervical lymph nodes using IVIS Spectrum system 
confirms 19F MRI, Related to Figures 3 and 4. Fluorescence images on the cryopreserved OCT-embedded lungs 
and cervical lymph nodes from all groups of mice were performed after the experimental end-point, three days 
post-infection. The scale bar represents fluorescence signal intensity. High signal intensities were detected in the 
lungs and lymph nodes of HCA-treated mice, confirming accumulation of ZPFCE-NP-labeled immune cells.  
 
 
 
 
 
 
 
 
 
Transparent method section 
 
Animals 
For the in vitro labeling experiments, macrophages were isolated from the peritoneum of 
C57/BL6 female mice (8-9 week-old). Female OT-II mice (6-8-week-old) bearing the MHCII-
restricted T cell receptor (TCR) for OVA323–339 were bred in house. For in vivo experiments, 
10-week-old male Balb/c mice (Janvier, Le Genest, France) were housed in KU Leuven animal 
housing facility with free access to food and water.  
All animal experiments were approved by the Ethical Committee of KU Leuven and were 
conducted according to the Belgian (Royal Decree of 29 May 2013), Flemish (Decision of the 
Flemish Government to adapt the Royal Decree of 29 May 2013, 17 February 2017) and 
European (Directive 2010/63/EU) regulations on the protection of animals used for scientific 
purposes.  
Synthesis of fluorinated Zonyl-PFCE nanoparticles 
The synthesis of biochemically inert perfluoro-15-crown-5-ether (PFCE) nanoparticles 
consisting of a PFCE liquid core emulsified by a monolayer of phospholipids was performed 
as described previously (Dewitte et al., 2013). The fluorosurfactant Zonyl® FSP (Du Pont, 
Delaware, USA) was incorporated in the lipid shell of PFCE nanoparticles, obtaining 
nanoparticles with an average size of 280nm. For the in vitro and in vivo experiments, ZPFCE-
NPs were coupled with either Cholestryl BODIPY® FLC12 or DiR fluorescent dye (both from 
Molecular Probes, Invitrogen, Merelbeke, Belgium).  
 
 
In vitro labeling of macrophages using ZPFCE nanoparticles 
For in vitro labeling, cells were incubated with ZPFCE-NPs at fluorine concentration of 0.5, 1 
and 10mM for 1h at 37°C in 5% CO2 in ultra-low attachment plates (Corning Costar, 
Kennebunk, ME, USA). For positive selection of labeled macrophages, cells were analyzed for 
surface marker expression after pre-incubation with the Fc receptor blocking antibody anti-
CD16/CD32 (eBioscience, San Diego, CA, USA) and staining using anti-F4/80 and anti-
CD11/b (eBioscience, San Diego, CA, USA) to perform quantitative flow cytometric analyses.  
Toxicological assay on ZPFCE-NP labeled macrophages 
Primary macrophages were labeled with different concentrations of ZPFCE-NPs. Surface 
staining with anti-F4/80 (eBiosciences) was performed to identify macrophages by microscopic 
analysis. Following exposure to nanoparticles, immune cells were stained to assess cell 
viability, cytoskeletal changes and oxidative stress. Data analysis was performed using a high-
content InCell 2000 analyzer (GE Healthcare Life Sciences, Diegem, Belgium) as previously 
described (Manshian et al., 2014). 
Determination of cytokine secretion by ZPFCE-NP labeled macrophages 
For cytokine measurement, ZPFCE-NP labeled macrophages were co-cultured in the presence 
or absence of 1µg/mL lipopolysaccharides (Sigma Aldrich, Overijse, Belgium) for 24h. 
Supernatants were collected and measurements of IL-10, IL-1beta and TNF-alpha were 
performed using a customized MSD V-PLEX mouse proinflammatory kit (Mesoscale, 
Maryland, USA). Readings were performed using a MESO QuickPlex SQ120 plate reader 
(Mesoscale, Maryland, USA). 
 
 
In vitro adaptive immune test on ZPFCE labeled macrophages 
Splenocytes from OTII transgenic mice were homogenized and negative selection of purified 
total CD4+ T cells was performed using a cocktail of antibodies for CD16/CD32, CD11b, 
CD11c, B220, MHC-II and CD8 markers. Contaminating, bead-bound cells were removed 
using sheep-anti-rat IgG paramagnetic beads, according to the manufacture’s specifications 
(Dynabeads, Invitrogen Merelbeke, Belgium). Purity of samples (>95%) was routinely assessed 
by flow cytometry. Purified OTII-transgenic CD4+ T cells were co-incubated with ZPFCE-NP 
labeled macrophages in a 96 well plate together with variable doses of anti-TCR b5.1/b5.2 
(OTII) peptide at concentrations of 0, 0.1, 1, 10μg/ml for 1-3 days at 37°C under 5% CO2 for 
1h. To prevent non-specific binding all surface stains were performed in the presence of anti-
CD16/CD32. For macrophages, the antibodies F4/80-PerCPCy5.5, CD45-APC-eFluor780 and 
CD11b-eFluor450 were used. To stain T cells, CD44-FITC, TCRb5.1/5.2-PE, CD62L-Per 
CPCy5.5, CD69-PECy7 and CD4-eFluor450 were used to assess effector, memory and naïve 
CD4+ T cell subsets using flow cytometry. All antibodies were purchased from eBioscience 
(San Diego, CA, USA). 
Murine models of invasive pulmonary aspergillosis  
To develop a non-neutropenic IPA model, mice were injected subcutaneously (s.c.) with 9mg 
hydrocortisone acetate per 25g body weight (Sigma-Aldrich, USP, Overijse, Belgium ) one and 
three days before inoculation with A. fumigatus (HCA group, n=9). To induce neutropenia, 
200mg kg-1 body weight cyclophosphamide (Sigma-Aldrich, USP, Overijse, Belgium) was 
injected intraperitoneally (i.p.) one and three days before inoculation with A. fumigatus (CY 
group, n=9). Infected immunocompetent mice (I-IC group, n=4) and non-infected 
immunocompetent mice (N-IC, n=3) were included as control groups. 
The Fluc+ A. fumigatus strain 2/7/1 was generously provided by M. Brock (School of Life 
Sciences, University of Nottingham, UK). The strain was cultured and conidia were harvested 
using a previously described protocol (Poelmans et al., 2016). On day of infection (day 0), HCA 
and infected immunocompetent groups (I-IC group, n=4) were intranasally instilled with 1×106 
spores. The CY group was inoculated with 5×105 spores based on the protocol described 
previously (Poelmans et al., 2016). ZPFCE-NPs were administered via tail vein 1h prior to MRI 
acquisition on day 0 and day 1. On the day of inoculation (day 0), MRI experiments were 
performed on all mice groups 4h after the administration of spores. All murine groups were 
monitored for weight loss and posture changes starting from day 0 to detect onset of disease 
symptoms and to define the humane end-points. 
Longitudinal in vivo fluorine (19F) magnetic resonance imaging  
Animals were anesthetized by intraperitoneal (i.p.) injections of ketamine (45-60 mg kg-1, 
Nimatek, Eurovet animal health, Bladel, The Netherlands) and Medetomidine (0.6-0.8 mg kg-
1, Domitor, The Orion Pharma, Espoo, Finland) solution. In vivo longitudinal follow-up of all 
murine groups was performed using 1H and 19F MRI on a 9.4T preclinical MRI scanner (Bruker 
Biospec 94/20, Ettlingen, Germany). After the MR acquisition, injections of atipamezole 
(Antisedan, The Orion Pharma, Espoo, Finland) were administered i.p. to reverse the effects of 
anesthesia. Throughout the MR imaging experiments, body temperature and respiration rate of 
the animals were monitored and maintained to 37°C and 60-80 min-1, respectively.  
A purpose-built dual-tuned radio frequency surface coil was used to acquire fluorine and 1H 
MR images. For all in vivo MRI experiments, 2D RARE (Rapid Acquisition with Relaxation 
Enhancement) MRI was performed using the following acquisition parameters: 1H MRI, 
repetition time (TR) = 3500ms, echo time (TE) = 6.12ms, spatial resolution = 
0.156mm×0.156mm, slice thickness = 1mm. For 19F MRI, TR = 5388ms, TE = 6.11ms, spatial 
resolution = 1.25mm×1.25mm, slice thickness = 2mm were used. A reference tube containing 
30mM of ZPFCE-NPs embedded in agar was placed next to the abdomen of the animal during 
the MR acquisition to allow quantification of fluorine atoms. For both 1H and 19F MR images, 
data were acquired with the same localization (placement, orientation of slice packages). 
Quantification of 19F MR signal and data processing 
Prior to the MR signal quantification, images were reconstructed using the Paravison 5.1 
software (Bruker Biospin, Ettlingen, Germany). For post processing, MR images were exported 
to the MeVislab software version 2.6.1 (MeVis Medical Solutions AG, Bremen, Germany). 
Gaussian smoothing was applied to the 19F MR images. Before masking the fluorine images, 
interval thresholding was performed by applying a value higher than the background noise. 
Masked 19F MR images were rescaled to the same matrix size as the 1H MR images before 
superimposing them over each other. To calculate the amount of fluorine atoms/voxel, the 
processed 19F MR images were analyzed slice-wise using the Fiji software, version 1.49a (South 
Carolina, USA) by drawing the region of interests on the fluorine hot spots in the lungs and the 
lymph node regions, which were identified based on the anatomical 1H MR images. For 
quantification, regions were compared with the reference tube that contained 30mM ZPFCE-
NPs. Cumulative 1H image scoring was performed on 1H images of all murine groups from day 
0 to day 3. Based on the visual observations, lung lesions were identified and a scoring system 
was used to assign a value for the quantification of signal intensities corresponding to the 
disease development as described previously (Petraitiene et al., 2002; Petraitis et al., 2003). 
Ex vivo bioluminescence imaging  
On day 3, the animals were euthanized and the lungs were inflated with 0.5ml D-luciferin 
(7.5mg) (Promega, Leiden, The Netherlands) by inserting a 22-gauge catheter (Terumo, 
Heverlee, Belgium) into the trachea. The lungs were immediately placed into the flow chamber 
to perform ex vivo BLI acquisitions on the IVIS Spectrum imaging system (Perkin Elmer, 
Massachusetts, USA). Data were analyzed using Living Image® software version 4.5.5 (Perkin 
Elmer, Massachusetts, USA).  
Differential white blood cell measurements  
For the differential blood cell counting, mice were euthanized under deep terminal anesthesia 
and blood was withdrawn using a 25-gauge needle (Terumo, Heverlee, Belgium) from the left 
ventricles of the beating heart through cardiac puncturing. Total collected blood volume was 
0.3 ml from each mouse. To prevent coagulation of blood, 30µl of tri-sodium citrate, 3.8% w/v 
(VWR, Belgium) was added to the blood collection tubes. Blood cell counts were performed 
on an ADVIA®2120i hemocytometer, version 5.4 (Siemens Healthcare, GmbH, Erlangen, 
Germany).  
Colony-forming unit (CFU) measurements 
After the ex vivo BLI acquisition, the right lung lobes were collected in 600µl PBS and 
homogenized to obtain suspensions of lung tissue. Lung homogenates were plated on 
Sabouraud agar, followed by an incubation period of 2-3 days at 30°C for manual counting of 
CFUs.  
Flow cytometry and microscopy 
Flow cytometry acquisitions were performed on a GalliosTM flow cytometer (Beckman Coulter, 
Brea, California, USA). For the data analyses, a FlowJo software, version 10.4.2 (FlowJo LLC, 
Ashland, Oregon, USA) was used. Microscopic images were acquired using a confocal 
microscope (Nikon, Tokyo, Japan) and analyzed using Fiji software, version 1.49a (South 
Carolina, USA). 
Ex vivo optical imaging of lungs and cervical lymph nodes 
Ex vivo fluorescence imaging was performed on the lungs and cervical lymph nodes (LN) of 
all animals using the IVIS Spectrum imaging system (Perkin Elmer Massachusetts, USA). For 
the acquisition of data, parameters used are as following: exposure time = 10sec, 740nm 
excitation and 800nm emission filters with medium binning. Data analysis was performed using 
the Living Image® software, version 4.5.5 (Perkin Elmer, Massachusetts, USA). 
Histology and immunohistochemistry 
Right lung lobes were fixed in 4% PFA and embedded in paraffin. For visualization of fungi, 
lungs were sectioned (5µm) and stained with Periodic acid-Schiff (PAS) agent as described 
(Poelmans et al., 2016). Brightfield images were acquired using ZEISS Axio Scan.Z1 Digital 
Slide Scanner (Carl Zeiss, Oberkochen, Germany). For immunoflurosence, left lung lobes were 
fresh frozen in OCT (optimum cutting temperature) formulation and cryosections (11µm) were 
fixed in 4% paraformaldehyde and stained according to manufacturer’s protocol. For staining 
of the sections following monoclonal antibodies were used: GR1 (RB6-8C5, eBioscience), 
CD11b (M1/70, Biolegend), CD11c biotin (N418, eBioscience). For the staining of immune 
cells, the following detection antibodies were used: Donkey anti-Rat 488, Streptavidin 546, (all 
from Molecular Probes). Images were acquired using a EVOS FL Auto 2 microscope (Fisher 
Scientific, Merelbeke, Belgium). 
Statistical analysis 
For statistical analyses, One-way and Two-way ANOVA tests were performed together with 
Bonferroni multiple comparison test to compare the different animal groups using the 
GraphPad Prism software®, version 5.04 (La Jolla, CA, USA). 
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